GE HealthCare has introduced the latest Invenia Automated Breast Ultrasound (ABUS) Premium to expedite scanning while driving early detection of cancer in dense breasts.
This AI-driven latest three-dimensional ultrasound technology is aimed at improving supplemental breast cancer screening and exam readings for patients with dense breast tissue.
Go deeper with GlobalData
It is tailored to handle large patient volumes, ensuring quality imaging and enhanced clinical confidence.
Invenia ABUS includes the newly integrated Verisound AI and AI Assistant, enabling quicker and more consistent scanning and reading.
The new Verisound AI tools, including Scan Quality Assessment and Auto Nipple Detection, claim to assist clinicians in ensuring proper coverage of the breast as well as their positioning during exams.
In addition, the Fast Scan tool can accelerate scan speed by up to 40%, and the cSound Imageformer offers “consistent, high-resolution” images.
For expedited and streamlined exam reviews, physicians can utilise the technology with AI Assistant, which allows for rapid interpretation of patient exams, even remotely.
AI tool integration in reviewing ABUS 3D datasets leverages algorithms to support the identification and characterisation of lesions in the breast, potentially enhancing reading “efficiency” and tackling staffing challenges.
The technology is said to decrease unnecessary biopsies by offering certain features of the image that help differentiate malignant tumours, allowing for earlier escalation of care.
It minimises exposure to radiation or contrast injection, further enhancing patient safety.
Its new “Reverse Curve” transducer and selectable compression levels ensure the exam is tailored to individual comfort.
GE HealthCare noted that the technology is set to be launched in prime nations throughout the year and has secured the US Food and Drug Administration’s premarket approval.
GE HealthCare comprehensive care ultrasound CEO Karley Yoder said: “Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages.
“Invenia ABUS Premium equipped with AI has the potential to optimise clinicians’ screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts.”
This launch follows the company’s partnership with NVIDIA to develop autonomous diagnostic imaging tools, focusing initially on X-ray and ultrasound technologies.
